$MDT — AVOID 📊 | 6 MONTHS THESIS

🧭 Conviction: MED Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and intern 🎯 FQ4 FY2026 (ends Apr) | reported Jun 03 | Rev $9.8B | Adj EPS $1.55 vs $1.56 🔴 💡 Consensus expected $1.56, but the miss was marginal. The market is pricing in continued stagnation or decline (implied -4.6% FCF growth) despite organic growth of 6.6%. The gap is that results are not declining, but the market treats it as a no-growth/value trap. 🏢 Business Quality: 6/10 📊 Valuation: fair 🔮 Catalyst: Next quarterly earnings (FQ1 FY2027, estimated Sept 2026) ⚖️ Avoid: unfavorable reward/risk (0.7:1), no imminent catalyst, and low-quality earnings make MDT a value trap at current levels despite a reasonable non-GAAP P/E. 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/MDT0710 Also in play: $LLY $JNJ $ABBV $UNH $MRK

🧭 Conviction: MED